TaiMed Biologics Inc. (TaiMed) and the School of Pharmacy at National Taiwan University (NTU) signed a Memorandum of Understanding (MOU) on 10 June 2025 to establish a collaborative framework for an internship and training program. This partnership aims to provide NTU students with hands-on exposure to the biotechnology and biopharmaceutical industries, deepening their understanding of practical drug development processes. The initiative is designed to strengthen students’ applied professional skills and bridge the gap between academic learning and industry practice — laying a solid foundation for future careers and addressing the urgent demand for high-caliber research and development talent.

The internship program will be executed in alignment with NTU's academic curriculum and implemented after both parties finalize the detailed plan. The initial program will focus on on-site training at TaiMed’s facilities, with a total duration of 16 weeks and equivalent to 13 academic credits. During the internship, students will return to NTU once mid-term to deliver a progress report, and will conclude with a final presentation on their experience and outcomes.

“We are honored to partner with the NTU School of Pharmacy to offer formal internship opportunities to students enrolled in the Biopharmaceutical Sciences Bachelor's Program,” said Dr. Jimmy Chang, CEO of TaiMed Biologics. “By participating directly in the drug development process, students will enhance their professional skills, foster a stronger connection between theory and practice, and be better prepared to transition into the workforce.”

Founded in 2007, TaiMed Biologics is dedicated to the development of innovative biologics, with a core focus on novel therapies for HIV. The company’s lead product, ibalizumab (brand name: Trogarzo®), was approved by the U.S. Food and Drug Administration (FDA) in 2018, making it the first and only monoclonal antibody approved for the treatment of HIV.

TaiMed is currently advancing the development of long-acting biologics and antibody-drug conjugates (ADCs) to expand its innovative pipeline. In addition, TaiMed’s Zhubei manufacturing site is actively expanding its capabilities in contract development and manufacturing (CDMO) services, providing end-to-end support for the pharmaceutical industry. Through this partnership with NTU, TaiMed aims to offer students a professional and high-quality internship environment, jointly fostering the growth of Taiwan’s biopharmaceutical industry and cultivating the next generation of talent — achieving a win-win outcome for both academia and industry.